Multivariate analysis of plasma metabolites in children with autism spectrum disorder and gastrointestinal symptoms before and after microbiota transfer therapy

James B. Adams, Troy Vargason, Dae Wook Kang, Rosa Krajmalnik-Brown, Juergen Hahn

Research output: Contribution to journalArticle

Abstract

Current diagnosis of autism spectrum disorder (ASD) is based on assessment of behavioral symptoms, although there is strong evidence that ASD affects multiple organ systems including the gastrointestinal (GI) tract. This study used Fisher discriminant analysis (FDA) to evaluate plasma metabolites from 18 children with ASD and chronic GI problems (ASD + GI cohort) and 20 typically developing (TD) children without GI problems (TD - GI cohort). Using three plasma metabolites that may represent three general groups of metabolic abnormalities, it was possible to distinguish the ASD + GI cohort from the TD - GI cohort with 94% sensitivity and 100% specificity after leave-one-out cross-validation. After the ASD + GI participants underwent Microbiota Transfer Therapy with significant improvement in GI and ASD-related symptoms, their metabolic profiles shifted significantly to become more similar to the TD - GI group, indicating potential utility of this combination of plasma metabolites as a biomarker for treatment efficacy. Two of the metabolites, sarcosine and inosine 50-monophosphate, improved greatly after treatment. The third metabolite, tyramine O-sulfate, showed no change in median value, suggesting it and correlated metabolites to be a possible target for future therapies. Since it is unclear whether the observed differences are due to metabolic abnormalities associated with ASD or with GI symptoms (or contributions from both), future studies aiming to classify ASD should feature TD participants with GI symptoms and have larger sample sizes to improve confidence in the results.

Original languageEnglish (US)
Article number806
JournalProcesses
Volume7
Issue number11
DOIs
StatePublished - Nov 1 2019

Fingerprint

Metabolites
Plasmas
Sarcosine
Inosine
Biomarkers
Discriminant analysis
Multivariate Analysis

Keywords

  • Autism spectrum disorder
  • Biomarker
  • Co-occurring conditions
  • Fecal microbiota transplant
  • Fisher discriminant analysis
  • Gastrointestinal symptoms
  • Leave-one-out cross-validation
  • Multivariate statistics
  • Plasma metabolites

ASJC Scopus subject areas

  • Bioengineering
  • Chemical Engineering (miscellaneous)
  • Process Chemistry and Technology

Cite this

Multivariate analysis of plasma metabolites in children with autism spectrum disorder and gastrointestinal symptoms before and after microbiota transfer therapy. / Adams, James B.; Vargason, Troy; Kang, Dae Wook; Krajmalnik-Brown, Rosa; Hahn, Juergen.

In: Processes, Vol. 7, No. 11, 806, 01.11.2019.

Research output: Contribution to journalArticle

@article{7fbfcf1ea6b949e98205788682906fb7,
title = "Multivariate analysis of plasma metabolites in children with autism spectrum disorder and gastrointestinal symptoms before and after microbiota transfer therapy",
abstract = "Current diagnosis of autism spectrum disorder (ASD) is based on assessment of behavioral symptoms, although there is strong evidence that ASD affects multiple organ systems including the gastrointestinal (GI) tract. This study used Fisher discriminant analysis (FDA) to evaluate plasma metabolites from 18 children with ASD and chronic GI problems (ASD + GI cohort) and 20 typically developing (TD) children without GI problems (TD - GI cohort). Using three plasma metabolites that may represent three general groups of metabolic abnormalities, it was possible to distinguish the ASD + GI cohort from the TD - GI cohort with 94{\%} sensitivity and 100{\%} specificity after leave-one-out cross-validation. After the ASD + GI participants underwent Microbiota Transfer Therapy with significant improvement in GI and ASD-related symptoms, their metabolic profiles shifted significantly to become more similar to the TD - GI group, indicating potential utility of this combination of plasma metabolites as a biomarker for treatment efficacy. Two of the metabolites, sarcosine and inosine 50-monophosphate, improved greatly after treatment. The third metabolite, tyramine O-sulfate, showed no change in median value, suggesting it and correlated metabolites to be a possible target for future therapies. Since it is unclear whether the observed differences are due to metabolic abnormalities associated with ASD or with GI symptoms (or contributions from both), future studies aiming to classify ASD should feature TD participants with GI symptoms and have larger sample sizes to improve confidence in the results.",
keywords = "Autism spectrum disorder, Biomarker, Co-occurring conditions, Fecal microbiota transplant, Fisher discriminant analysis, Gastrointestinal symptoms, Leave-one-out cross-validation, Multivariate statistics, Plasma metabolites",
author = "Adams, {James B.} and Troy Vargason and Kang, {Dae Wook} and Rosa Krajmalnik-Brown and Juergen Hahn",
year = "2019",
month = "11",
day = "1",
doi = "10.3390/pr7110806",
language = "English (US)",
volume = "7",
journal = "Processes",
issn = "2227-9717",
publisher = "MDPI AG",
number = "11",

}

TY - JOUR

T1 - Multivariate analysis of plasma metabolites in children with autism spectrum disorder and gastrointestinal symptoms before and after microbiota transfer therapy

AU - Adams, James B.

AU - Vargason, Troy

AU - Kang, Dae Wook

AU - Krajmalnik-Brown, Rosa

AU - Hahn, Juergen

PY - 2019/11/1

Y1 - 2019/11/1

N2 - Current diagnosis of autism spectrum disorder (ASD) is based on assessment of behavioral symptoms, although there is strong evidence that ASD affects multiple organ systems including the gastrointestinal (GI) tract. This study used Fisher discriminant analysis (FDA) to evaluate plasma metabolites from 18 children with ASD and chronic GI problems (ASD + GI cohort) and 20 typically developing (TD) children without GI problems (TD - GI cohort). Using three plasma metabolites that may represent three general groups of metabolic abnormalities, it was possible to distinguish the ASD + GI cohort from the TD - GI cohort with 94% sensitivity and 100% specificity after leave-one-out cross-validation. After the ASD + GI participants underwent Microbiota Transfer Therapy with significant improvement in GI and ASD-related symptoms, their metabolic profiles shifted significantly to become more similar to the TD - GI group, indicating potential utility of this combination of plasma metabolites as a biomarker for treatment efficacy. Two of the metabolites, sarcosine and inosine 50-monophosphate, improved greatly after treatment. The third metabolite, tyramine O-sulfate, showed no change in median value, suggesting it and correlated metabolites to be a possible target for future therapies. Since it is unclear whether the observed differences are due to metabolic abnormalities associated with ASD or with GI symptoms (or contributions from both), future studies aiming to classify ASD should feature TD participants with GI symptoms and have larger sample sizes to improve confidence in the results.

AB - Current diagnosis of autism spectrum disorder (ASD) is based on assessment of behavioral symptoms, although there is strong evidence that ASD affects multiple organ systems including the gastrointestinal (GI) tract. This study used Fisher discriminant analysis (FDA) to evaluate plasma metabolites from 18 children with ASD and chronic GI problems (ASD + GI cohort) and 20 typically developing (TD) children without GI problems (TD - GI cohort). Using three plasma metabolites that may represent three general groups of metabolic abnormalities, it was possible to distinguish the ASD + GI cohort from the TD - GI cohort with 94% sensitivity and 100% specificity after leave-one-out cross-validation. After the ASD + GI participants underwent Microbiota Transfer Therapy with significant improvement in GI and ASD-related symptoms, their metabolic profiles shifted significantly to become more similar to the TD - GI group, indicating potential utility of this combination of plasma metabolites as a biomarker for treatment efficacy. Two of the metabolites, sarcosine and inosine 50-monophosphate, improved greatly after treatment. The third metabolite, tyramine O-sulfate, showed no change in median value, suggesting it and correlated metabolites to be a possible target for future therapies. Since it is unclear whether the observed differences are due to metabolic abnormalities associated with ASD or with GI symptoms (or contributions from both), future studies aiming to classify ASD should feature TD participants with GI symptoms and have larger sample sizes to improve confidence in the results.

KW - Autism spectrum disorder

KW - Biomarker

KW - Co-occurring conditions

KW - Fecal microbiota transplant

KW - Fisher discriminant analysis

KW - Gastrointestinal symptoms

KW - Leave-one-out cross-validation

KW - Multivariate statistics

KW - Plasma metabolites

UR - http://www.scopus.com/inward/record.url?scp=85075573915&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075573915&partnerID=8YFLogxK

U2 - 10.3390/pr7110806

DO - 10.3390/pr7110806

M3 - Article

AN - SCOPUS:85075573915

VL - 7

JO - Processes

JF - Processes

SN - 2227-9717

IS - 11

M1 - 806

ER -